Statistics for The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Total visits
| views | |
|---|---|
| The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer | 87 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms-1624615.pdf | 87 |
| java.util.UUID:622bba97-e8c9-4447-a723-98d117b30b2d | 46 |
| java.util.UUID:905db75d-d761-480e-9814-141d87fd33de | 14 |
| java.util.UUID:ea33787b-51e3-4518-8a5d-8a077969ff4a | 5 |
Top country views
| views | |
|---|---|
| United States | 68 |
| Canada | 2 |
| Malaysia | 2 |
| Belgium | 1 |
| China | 1 |
| France | 1 |
| Russia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 40 |
| Fairfield | 8 |
| Houston | 4 |
| Ann Arbor | 2 |
| Cambridge | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Baltimore | 1 |
| Chicago | 1 |
| Moscow | 1 |
| Nanterre | 1 |
| Seremban | 1 |
| Washington | 1 |
| Zaventem | 1 |